Celcuity Inc. Common Stock
CELC
$93.53
+3.27%
Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors, with its lead candidate gedatolisib, a kinase inhibitor of the PI3K/AKT/mTOR pathway, currently in Phase 3 trials for HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer. The company is positioned as a niche player in the oncology space, differentiated by its comprehensive PAM pathway inhibition and a companion diagnostic strategy. The current investor narrative centers on the upcoming FDA review and potential approval of gedatolisib, which has driven a massive stock surge over the past year, but also introduces significant regulatory and commercial execution risk as the company remains pre-revenue.…
CELC
Celcuity Inc. Common Stock
$93.53
Related headlines
Investment Opinion: Should I buy CELC Today?
Rating: Buy (with high risk). The consensus is Strong Buy with an average target of $161.09, implying 72.2% upside. The thesis is that gedatolisib will gain FDA approval and become a standard-of-care in HR+/HER2- breast cancer, driving significant revenue. Supporting evidence includes positive Phase 3 data, a large addressable market, and institutional buying. However, the stock is pre-revenue and trades at extreme multiples, so the risk is substantial.
Sign up to view all
CELC 12-Month Price Forecast
The AI assessment leans bullish due to the strong analyst conviction and positive clinical data, but confidence is medium given the binary regulatory risk. The stock's 38% drawdown from highs suggests the market is already pricing in some risk, but the potential upside to $161 is significant. If the FDA approves gedatolisib, the stock could rally to the high target; if not, it could halve. The stance would be upgraded to high confidence if the FDA accepts the NDA and sets a PDUFA date, or downgraded if safety concerns emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celcuity Inc. Common Stock's 12-month outlook, with a consensus price target around $161.09 and implied upside of +72.2% versus the current price.
Average Target
$161.09
0 analysts
Implied Upside
+72.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $177
Analyst target range
Celcuity is covered by 11 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.17). The average target price is $161.09, implying a substantial upside of +72.2% from the current price of $93.53. The target range is $140.00 to $177.00, with the low target still representing a 49.7% upside, indicating high conviction among analysts. Recent ratings have been consistently positive, with firms like HC Wainwright, Wells Fargo, and Needham maintaining or initiating Buy ratings, and no downgrades in the past few months, suggesting strong confidence in the company's prospects.
Bulls vs Bears: CELC Investment Factors
Celcuity presents a classic binary risk/reward: the bull case rests on gedatolisib's approval and blockbuster potential, supported by a Strong Buy consensus and 72% analyst upside, while the bear case highlights a pre-revenue company with widening losses, extreme valuation, and regulatory uncertainty. Currently, the evidence slightly favors the bull side given the positive Phase 3 data and institutional conviction, but the stock's 38% drawdown from highs shows the market is already pricing in significant risk. The single most important tension is the FDA's decision on gedatolisib—approval could send the stock to analyst targets, while a rejection or delay could cut the price by half or more. Investors must weigh the high probability of approval (implied by analyst targets) against the severe consequences of failure.
Bullish
- Strong Buy consensus with 72% upside: 11 analysts rate CELC a Strong Buy (mean 1.17) with an average target of $161.09, implying 72.2% upside from the current $93.53. The low target of $140 still offers 49.7% upside, reflecting high conviction in gedatolisib's approval.
- Phase 3 VIKTORIA-1 data positive: The Phase 3 trial in HR+/HER2- breast cancer completed enrollment and reported positive results for PIK3CA WT tumors, a key efficacy signal. This de-risks the regulatory path and supports the upcoming FDA submission.
- Institutional investors increasing stakes: Recent filings show a fund added $170 million and another $17 million, creating top-two positions. This signals sophisticated investors are betting on FDA approval and commercial success, aligning with the stock's 85.6% 1-year gain.
- Large addressable market in oncology: Gedatolisib targets multiple solid tumors, including breast and prostate cancers, with a differentiated PAM pathway inhibitor. The estimated revenue consensus of $1.75 billion by 2026 implies significant commercial potential if approved.
Bearish
- Pre-revenue with widening losses: CELC has zero revenue and Q1 2026 net loss widened to -$52.84M from -$37.0M a year ago. EBITDA was -$46.71M, and FCF TTM is -$172.93M, indicating escalating cash burn with no near-term profitability.
- Extreme valuation with no earnings: Price-to-book is 52.11 and EV/EBITDA is -32.99, reflecting the market pricing in massive future value. The negative PEG of -0.786 and forward PE of -1169 are not meaningful, but the stock is priced for perfection.
- Regulatory and clinical risk: The stock's fate hinges on FDA approval of gedatolisib, which is not guaranteed. Any delay, CRL, or safety issue could trigger a sharp selloff, as seen in the 43.25% max drawdown over the past year.
- High volatility and momentum reversal: The stock fell 32.3% in the last 3 months and is 38% off its 52-week high of $151.02. Beta of 0.2 understates idiosyncratic risk; the stock's 1-year gain of 85.6% vs. SPY's 20.5% shows extreme relative strength that could unwind.
CELC Technical Analysis
Celcuity's stock has exhibited a dramatic uptrend over the past year, with a 1-year price change of +85.65%, though it has experienced significant volatility. The current price of $93.53 sits at approximately 45% of its 52-week range (between $44.42 low and $151.02 high), indicating a substantial pullback from its highs. This positioning suggests the stock is in a correction phase after a strong rally, with the price having retreated from its peak but still well above its low, reflecting a mix of momentum and uncertainty.
Beta
0.20
0.20x market volatility
Max Drawdown
-43.3%
Largest decline past year
52-Week Range
$44-$151
Price range past year
Annual Return
+85.6%
Cumulative gain past year
| Period | CELC Return | S&P 500 |
|---|---|---|
| 1m | +3.8% | +3.6% |
| 3m | -32.3% | +2.7% |
| 6m | -10.7% | +11.4% |
| 1y | +85.6% | +18.7% |
| ytd | -7.0% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CELC Fundamental Analysis
Celcuity is a pre-revenue company, with zero revenue reported in the most recent quarter (Q1 2026) and all prior quarters, as it is still in clinical development. The company's net loss widened to -$52.84 million in Q1 2026 from -$36.997 million in Q1 2025, reflecting increased R&D spending of $33.06 million, up from $32.23 million year-over-year. The trajectory shows escalating losses as the company advances its late-stage trials, with EBITDA also negative at -$46.71 million for Q1 2026, indicating no near-term path to profitability without successful commercialization.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-172930000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CELC Overvalued?
Given that Celcuity has negative net income and no revenue, the most appropriate valuation metric is the price-to-sales ratio, but since revenue is zero, the PS ratio is undefined. Therefore, we must rely on alternative metrics like EV/EBITDA, which is -32.99, or price-to-book at 52.11, both indicating the market is pricing in significant future value. The forward PE of -1169.13 is not meaningful, but the negative PEG ratio of -0.786 suggests the market expects earnings growth, though the company is still loss-making.
PE
-26.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Celcuity is pre-revenue with no sales, and its net loss widened to -$52.84M in Q1 2026 from -$37.0M a year ago, reflecting increased R&D spending. The company's EBITDA was -$46.71M, and free cash flow TTM is -$172.93M, indicating a cash burn rate that requires frequent capital raises. With a debt-to-equity of 1.94 and a current ratio of 10.55, the company has liquidity but relies on equity financing, which dilutes shareholders. The lack of revenue concentration is not an issue, but the dependence on a single drug candidate (gedatolisib) for all future value creates extreme financial risk if the drug fails or is delayed.
FAQ
The key risks are: 1) Regulatory risk - FDA may reject gedatolisib or require additional trials, causing a stock drop of 50% or more. 2) Clinical risk - ongoing trials may show safety or efficacy issues. 3) Financial risk - the company has no revenue and burns cash, with a net loss of -$52.84M in Q1 2026, requiring future dilution. 4) Competitive risk - existing therapies like alpelisib and CDK4/6 inhibitors may limit market share. The most severe risk is FDA non-approval, which could send the stock to the 52-week low of $44.42.
The 12-month forecast is highly uncertain. In the bull case (40% probability), the stock could reach $140-$177 if the FDA approves gedatolisib and commercial launch is successful. In the base case (35% probability), the stock trades around $120-$161, assuming approval with some restrictions. In the bear case (25% probability), the stock could fall to $44-$90 if the FDA rejects the drug or delays approval. The most likely scenario is the base case, with approval but a slower revenue ramp, leading to a target near the analyst average of $161.
CELC is extremely overvalued on traditional metrics, with a price-to-book of 52.11 and a negative EV/EBITDA of -32.99, reflecting the market's high expectations for future revenue. The forward PE is -1169, which is meaningless for a pre-revenue company. However, relative to analyst targets, the stock is undervalued, with a 72% upside to the average target. The valuation implies the market expects gedatolisib to generate billions in revenue, which is possible but not guaranteed. If the drug fails, the stock could fall to the 52-week low of $44.42, representing a -52% loss.
CELC is a high-risk, high-reward biotech stock with a Strong Buy consensus and an average analyst target of $161.09, implying 72% upside from the current $93.53. However, the company is pre-revenue and depends on FDA approval of gedatolisib, which is a binary event. The stock has already fallen 38% from its high, offering a better entry point, but the downside to the 52-week low of $44.42 is -52%. It is a good buy for aggressive investors who believe in the drug's approval and can tolerate a potential 50% loss. For conservative investors, it is too speculative.
CELC is suitable for long-term investment (3-5 years) for investors who believe in the drug's potential and can withstand high volatility. The stock's beta is 0.2, but its actual volatility is much higher, as seen in its 43% max drawdown. Short-term trading is risky due to binary FDA events and the stock's 32% drop in the last 3 months. The company has no dividend and is pre-revenue, so it is not for income investors. A minimum holding period of 3 years is recommended to allow for FDA approval and commercial ramp, but investors should be prepared for a potential 50% loss in the interim.